I think reading into the delay in readouts = bad news is a little too pessimistic IMO. SI has previously said that the reasons for the delay were due to COVID and the increased workloads on senior management to get the ARDS trial up and running across the USA, including MIS-C. That alone has been a mammoth effort (21 hospitals have not been opened in USA, plus hospitals in Canada and Australia, plus any hospitals requiring MIS-C).
On top of this, they have been obviously busy taking blood samples of COVID patients and analyzing the data (on that point I had no idea they were allowed to do that, as surely they will be able to have a good understanding as of today as to how the drug is going - i.e. I am guessing the blood-work will show who has received Rem-L v placebo, and therefore they would have a good indicating of overall mortality in placebo v controlled group).
They have also been required to prepare for ODAC meeting and aGHVD (now failed) launch.
This kind of work cannot be done by middle management, but rather by the executive team. As such, there has not been the resources to then dedicate to CHF and CLBP and this was made clear that delays were due to COVID, not results. As such, if you are now doubting the word of senior management, then it's strange why you would remain invested in a company whose future relies on the competence of its management moreso than most other companies.
I for one take SI at his word that the delay has nothing to do with the results - i.e. why would SI be discussing potential partnership deals for CHF if he believed the results were poor?!
Also, food for thought - see the below sale of MYOK for $13B USD that has a platform drug for the heart. Goes to show that if MSB CHF is approved as to what our MC may be if a big pharma ever came knocking...
- Forums
- ASX - By Stock
- MSB
- Updated Broker Report: Bel Potter
Updated Broker Report: Bel Potter, page-85
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
SBW
Shekel Brainweigh reports a 50% revenue increase in its Retail Innovation suite and delivers the first batch of 20 Smart Bays to Hitachi as part of a larger order
BM8
Learn of the ASX-listed company that is well-placed to respond to the future global energy demand
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.569B |
Open | High | Low | Value | Volume |
$1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 12214 | $1.38 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.38 | 37660 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 12214 | 1.375 |
7 | 53796 | 1.370 |
7 | 53347 | 1.365 |
14 | 192096 | 1.360 |
3 | 45165 | 1.355 |
Price($) | Vol. | No. |
---|---|---|
1.380 | 37660 | 5 |
1.385 | 25000 | 1 |
1.390 | 56973 | 4 |
1.395 | 31284 | 2 |
1.400 | 146999 | 10 |
Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online